+关注
CharlieHtay
暂无个人介绍
IP属地：未知
91
关注
6
粉丝
0
主题
0
勋章
主贴
热门
CharlieHtay
2021-12-07
Ok
抱歉，原内容已删除
CharlieHtay
2021-08-04
Ok
SoftBank Builds a $5 Billion Stake in Pharma Giant Roche
CharlieHtay
2021-08-04
Ok
抱歉，原内容已删除
CharlieHtay
2021-08-04
Ok
抱歉，原内容已删除
CharlieHtay
2021-08-03
Ok
抱歉，原内容已删除
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4091059338128690","uuid":"4091059338128690","gmtCreate":1627956310959,"gmtModify":1629861931408,"name":"CharlieHtay","pinyin":"charliehtay","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/0ae33e398b0a3ea162ebb41390c87740","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":6,"headSize":91,"tweetSize":5,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.04.30","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.16","exceedPercentage":"93.22%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.02.10","exceedPercentage":"80.16%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":606512966,"gmtCreate":1638892175151,"gmtModify":1638892175389,"author":{"id":"4091059338128690","authorId":"4091059338128690","name":"CharlieHtay","avatar":"https://static.tigerbbs.com/0ae33e398b0a3ea162ebb41390c87740","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091059338128690","authorIdStr":"4091059338128690"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606512966","repostId":"2188528084","repostType":2,"isVote":1,"tweetType":1,"viewCount":760,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":807677779,"gmtCreate":1628037116191,"gmtModify":1633754214500,"author":{"id":"4091059338128690","authorId":"4091059338128690","name":"CharlieHtay","avatar":"https://static.tigerbbs.com/0ae33e398b0a3ea162ebb41390c87740","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091059338128690","authorIdStr":"4091059338128690"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/807677779","repostId":"2156209941","repostType":4,"repost":{"id":"2156209941","pubTimestamp":1628035381,"share":"https://www.laohu8.com/m/news/2156209941?lang=&edition=full","pubTime":"2021-08-04 08:03","market":"us","language":"en","title":"SoftBank Builds a $5 Billion Stake in Pharma Giant Roche","url":"https://stock-news.laohu8.com/highlight/detail?id=2156209941","media":"Bloomberg","summary":"Japanese firm’s stake makes it one of Roche’s top investors\nSoftBank believes Roche’s Genentech divi","content":"<ul>\n <li>Japanese firm’s stake makes it one of Roche’s top investors</li>\n <li>SoftBank believes Roche’s Genentech division is undervalued</li>\n</ul>\n<p>SoftBank Group Corp. has quietly built a $5 billion stake in Roche Holding AG, placing a bet on the pharmaceutical company’s strategy of using data to develop drugs, according to people familiar with the matter.</p>\n<p>The Japanese conglomerate is now <a href=\"https://laohu8.com/S/AONE.U\">one</a> of Roche’s largest investors, according to data compiled by Bloomberg.</p>\n<p>Roche’s sales have recently been boosted by its Covid-19 testing business. The company’s diagnostics unit reacted swiftly to the coronavirus pandemic, but the pharmaceuticals division, where aging cancer medicines face increasing competition, has had a more difficult time.</p>\n<p>Shares of the Basel, Switzerland-based company have risen 8.8% in the last 12 months, compared with a 14.7% gain in the MSCI World Pharma Biotech & Life Sciences index over the same period.</p>\n<p>The drugmaker has a dual-class share structure with separate voting and non-voting shares. The founding families own 50.1% of the voting class, while cross-town rival Novartis AG holds one-third. It’s unclear which types of shares SoftBank holds.</p>\n<p>SoftBank believes Roche’s Genentech division, which focuses on data-based drug discovery and development, is highly undervalued, one of the people said, all of whom asked not to be identified because the information is private. Roche last year hired Aviv Regev, a computational and systems biologist who was a core member of the Harvard University-affiliated Broad Institute, to lead the Genetech research unit.</p>\n<p>Roche is also developing a new pill for Covid-19 and an Alzheimer’s disease treatment. In June, the U.S. approved Biogen Inc.’s Alzheimer’s drug Aduhelm, which was seen as a positive sign for the Roche medicine.</p>\n<p>SoftBank has been increasingly focused on biotech and health care. It invested in Pacific Biosciences of California Inc., <a href=\"https://laohu8.com/S/ABCL\">AbCellera Biologics</a> and Sana Biotechnology. In February, Bloomberg News reported that SoftBank was planning to spend billions investing in public biotech companies, via its asset management arm SB Northstar.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SoftBank Builds a $5 Billion Stake in Pharma Giant Roche</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSoftBank Builds a $5 Billion Stake in Pharma Giant Roche\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-04 08:03 GMT+8 <a href=https://www.bloomberg.com/news/articles/2021-08-03/softbank-is-said-to-build-5-billion-stake-in-pharma-giant-roche?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Japanese firm’s stake makes it one of Roche’s top investors\nSoftBank believes Roche’s Genentech division is undervalued\n\nSoftBank Group Corp. has quietly built a $5 billion stake in Roche Holding AG, ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-03/softbank-is-said-to-build-5-billion-stake-in-pharma-giant-roche?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSFT":"微软","RHHBF":"Roche Holding Ltd","PACB":"Pacific Biosciences of Californi","SFTBY":"软银集团","RHHBY":"罗氏控股","BIIB":"渤健公司","AMZN":"亚马逊"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-03/softbank-is-said-to-build-5-billion-stake-in-pharma-giant-roche?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156209941","content_text":"Japanese firm’s stake makes it one of Roche’s top investors\nSoftBank believes Roche’s Genentech division is undervalued\n\nSoftBank Group Corp. has quietly built a $5 billion stake in Roche Holding AG, placing a bet on the pharmaceutical company’s strategy of using data to develop drugs, according to people familiar with the matter.\nThe Japanese conglomerate is now one of Roche’s largest investors, according to data compiled by Bloomberg.\nRoche’s sales have recently been boosted by its Covid-19 testing business. The company’s diagnostics unit reacted swiftly to the coronavirus pandemic, but the pharmaceuticals division, where aging cancer medicines face increasing competition, has had a more difficult time.\nShares of the Basel, Switzerland-based company have risen 8.8% in the last 12 months, compared with a 14.7% gain in the MSCI World Pharma Biotech & Life Sciences index over the same period.\nThe drugmaker has a dual-class share structure with separate voting and non-voting shares. The founding families own 50.1% of the voting class, while cross-town rival Novartis AG holds one-third. It’s unclear which types of shares SoftBank holds.\nSoftBank believes Roche’s Genentech division, which focuses on data-based drug discovery and development, is highly undervalued, one of the people said, all of whom asked not to be identified because the information is private. Roche last year hired Aviv Regev, a computational and systems biologist who was a core member of the Harvard University-affiliated Broad Institute, to lead the Genetech research unit.\nRoche is also developing a new pill for Covid-19 and an Alzheimer’s disease treatment. In June, the U.S. approved Biogen Inc.’s Alzheimer’s drug Aduhelm, which was seen as a positive sign for the Roche medicine.\nSoftBank has been increasingly focused on biotech and health care. It invested in Pacific Biosciences of California Inc., AbCellera Biologics and Sana Biotechnology. In February, Bloomberg News reported that SoftBank was planning to spend billions investing in public biotech companies, via its asset management arm SB Northstar.","news_type":1},"isVote":1,"tweetType":1,"viewCount":167,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807676542,"gmtCreate":1628036928886,"gmtModify":1633754218349,"author":{"id":"4091059338128690","authorId":"4091059338128690","name":"CharlieHtay","avatar":"https://static.tigerbbs.com/0ae33e398b0a3ea162ebb41390c87740","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091059338128690","authorIdStr":"4091059338128690"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/807676542","repostId":"1101001900","repostType":4,"isVote":1,"tweetType":1,"viewCount":51,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807678532,"gmtCreate":1628036899126,"gmtModify":1633754219399,"author":{"id":"4091059338128690","authorId":"4091059338128690","name":"CharlieHtay","avatar":"https://static.tigerbbs.com/0ae33e398b0a3ea162ebb41390c87740","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091059338128690","authorIdStr":"4091059338128690"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/807678532","repostId":"2156786341","repostType":4,"isVote":1,"tweetType":1,"viewCount":87,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":804477137,"gmtCreate":1627977423729,"gmtModify":1633754712896,"author":{"id":"4091059338128690","authorId":"4091059338128690","name":"CharlieHtay","avatar":"https://static.tigerbbs.com/0ae33e398b0a3ea162ebb41390c87740","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091059338128690","authorIdStr":"4091059338128690"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/804477137","repostId":"2156113951","repostType":4,"isVote":1,"tweetType":1,"viewCount":103,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":807677779,"gmtCreate":1628037116191,"gmtModify":1633754214500,"author":{"id":"4091059338128690","authorId":"4091059338128690","name":"CharlieHtay","avatar":"https://static.tigerbbs.com/0ae33e398b0a3ea162ebb41390c87740","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4091059338128690","idStr":"4091059338128690"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/807677779","repostId":"2156209941","repostType":4,"isVote":1,"tweetType":1,"viewCount":167,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":606512966,"gmtCreate":1638892175151,"gmtModify":1638892175389,"author":{"id":"4091059338128690","authorId":"4091059338128690","name":"CharlieHtay","avatar":"https://static.tigerbbs.com/0ae33e398b0a3ea162ebb41390c87740","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4091059338128690","idStr":"4091059338128690"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606512966","repostId":"2188528084","repostType":2,"repost":{"id":"2188528084","pubTimestamp":1638543717,"share":"https://www.laohu8.com/m/news/2188528084?lang=&edition=full","pubTime":"2021-12-03 23:01","market":"us","language":"en","title":"5 Warren Buffett Stocks Are Screaming Buys in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2188528084","media":"Motley Fool","summary":"Riding the Oracle of Omaha's coattails is often a moneymaking proposition.","content":"<p>Making money for shareholders has been in Warren Buffett's blood since taking over as CEO of <b>Berkshire Hathaway</b> (NYSE:BRK.A)(NYSE:BRK.B) in 1965. Over that time, he's led Berkshire to an average annual gain of about 20%, which translates into aggregate gains, including the year-to-date performance of the Class A shares (BRK.A), of approximately 3,500,000%. Gains like this are why the investing world pays close attention to what the Oracle of Omaha is buying and selling.</p>\n<p>Based on the latest 13F filing with the Securities and Exchange Commission, Berkshire Hathaway has stakes in 45 securities. Among these 45 holdings, five Warren Buffett stocks stand out as screaming buys in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e92116e97f06291ec28eda85974acb1b\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Berkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.</span></p>\n<h2>Amazon</h2>\n<p>While I'm well aware this isn't going to win any points for originality, e-commerce kingpin <b>Amazon</b> (NASDAQ:AMZN) remains a surefire stock to own in Buffett's portfolio.</p>\n<p>Most people are familiar with Amazon for its dominant online marketplace. According to an August report from eMarketer, Amazon is expected to handle 41.4% of all U.S. online sales in 2021. That's about 34 percentage points higher than the next-closest competitor. The key, though, is that the company has signed up 200 million people to a Prime membership worldwide. The annual fees collected from these members helps to buoy razor-thin retail margins and allows Amazon to consistently undercut brick-and-mortar retailers on price.</p>\n<p>However, the company's future rests with its considerably higher-margin segments, such as cloud infrastructure services. Amazon Web Services (AWS) accounted for only 13.4% of net sales in the third quarter, yet contributed 61.8% of the company's operating income. Even with online sales slowing as coronavirus vaccination rates tick higher and life returns to some semblance of normal, Amazon's critical highest-margin segments (AWS, subscriptions, and advertising) continue to grow rapidly.</p>\n<p>If Amazon were to simply hit the median price-to-operating cash flow it's been trading at for the past 11 years, we could be looking at a $10,000 a share company by mid-decade.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b18b49b2b35da2fc49e0a83b883d1c22\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Bristol Myers Squibb</h2>\n<p>Another Warren Buffett stock that's quickly become a screaming buy is pharmaceutical company <b>Bristol Myers Squibb</b> (NYSE:BMY).</p>\n<p>Bristol Myers' success is dependent on organically developing and growing its brand-name pharmaceutical portfolio, as well as leaning on acquisitions to push the needle higher.</p>\n<p>From an internal development perspective, some of the company's biggest wins include cancer immunotherapy Opdivo and oral anticoagulant Eliquis -- the latter of which was developed with <b>Pfizer</b>. Eliquis should push for $10 billion in sales for Bristol Myers this year, while Opdivo hit $7 billion in revenue last year. Opdivo is particularly intriguing given that it's being examined in dozens of clinical trials and has already received approval for 10 indications in the U.S. Label expansion opportunities, pricing power, and improved cancer screening diagnostics all have the potential to make this a $10 billion a year therapy.</p>\n<p>Bristol Myers also made waves with its November 2019 acquisition of cancer and immunology drugmaker Celgene. Buying Celgene added a handful of blockbuster drugs to Bristol's portfolio, including multiple myeloma treatment Revlimid, which will potentially top $13 billion in 2021 sales. Revlimid is protected from an onslaught of generic competition for four more years, which means Bristol Myers will be generating bountiful cash flow in the meantime.</p>\n<p>At just 7 times consensus forward-year earnings per share, it's an absolute steal.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a295212aa2b7c99c921b8afa2a4aa3a2\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/V\">Visa</a></h2>\n<p>The recent sell-off in payment processing behemoth <b>Visa</b> (NYSE:V) makes it a screaming buy, too.</p>\n<p>Over the past couple of months, Wall Street and investors have raised concerns about payment facilitators like <b>Square</b> or cryptocurrencies eating into Visa's dominance. However, these concerns seem unfounded given Visa's utter dominance of the processing space. As of 2018, it held a 53% share of U.S. credit card network purchase volume, which was more than 30 percentage points higher than the next-closest competitor. I should also mention the U.S. is the leading market for consumption in the world.</p>\n<p>Visa's outperformance is also a function of its lending avoidance. By sticking to the processing side of the equation, the company avoids having to set aside capital to cover credit delinquencies during recessions. Not having to cover credit/loan losses is a big reason why Visa rebounds faster than other financial stocks and maintains a profit margin north of 50%.</p>\n<p>And have I mentioned that Visa is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the smartest ways to play rapidly rising inflation? Since the company's fees are tied to the price of goods and services, its revenue and profits will grow as the price for goods and services rises.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1c5a0257bdd17a5ff3cf22a10de43ce0\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Teva Pharmaceutical Industries</h2>\n<p>The cheapest stock in Warren Buffett's portfolio, brand-name and generic-drug company <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA), is begging to be bought as well. Teva can currently be purchased for a little more than 3 times Wall Street's consensus earnings per share in 2021 and 2022.</p>\n<p>Unlike Amazon, Bristol Myers, and Visa, Teva hasn't been firing on all cylinders. Since 2016, the company settled a bribery scandal, buried itself in debt after overpaying for generic-drugmaker Actavis, and has faced a mountain of litigation concerning its role in the opioid epidemic. But while there's reason to not give Teva a valuation premium, an earnings multiple of 3 is overly pessimistic given the steps being taken to right the ship.</p>\n<p>In late 2017, Kare Schultz took over as CEO. He's a turnaround specialist who's taken clear steps to improve the business. During his tenure, net debt has been reduced from over $34 billion to around $22 billion, and annual operating expenses have been cut by a double-digit percentage. Teva is leaner than it's been in years and is capable of maintaining annual operating cash flow of $2 billion (or higher).</p>\n<p>Furthermore, there's light at the end of the tunnel when it comes to opioid litigation. A trial in California recently went in favor of drugmakers, which could put some bargaining power back in Teva's court. If Schultz can negotiate a national settlement where free or reduced-cost medicine, not cash, is the lure, Teva could probably double very quickly.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7343c3ce7330b86321a8ec9384d4baea\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Bank of America</h2>\n<p>The final Warren Buffett stock to buy hand over fist in December is banking juggernaut <b>Bank of America</b> (NYSE:BAC).</p>\n<p>Bank stocks like BofA are on the cusp of hitting their growth sweet spot. With inflation picking up, the Federal Reserve will more than likely need to act in 2022 or 2023 to raise interest rates. Boosting the federal funds target rate will lift the net interest income-earning potential of banks with outstanding variable-rate loans.</p>\n<p>Among money-center banks, none is more interest-sensitive than Bank of America. The company's third-quarter earnings presentation points out that a 100-basis-point parallel shift in the interest rate yield curve would generate an estimated $7.2 billion in added net interest income over 12 months. Although we're unlikely to see a 100-basis-point shift in 12 months, we are on the verge of seeing higher interest rates significantly bolster BofA's profit potential.</p>\n<p>The other impressive aspect of Warren Buffett's second-largest holding is its digitization efforts. Though you probably don't think of Bank of America as a tech-savvy business, the number of digital active users has grown to nearly 41 million, with 43% of all sales in the third quarter coming from online or mobile banking. This push to digitize has allowed the company to consolidate some of its branches in order to reduce costs.</p>\n<p>Bank of America should be a no-brainer buy as it enters the sweet spot of its growth cycle.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Warren Buffett Stocks Are Screaming Buys in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Warren Buffett Stocks Are Screaming Buys in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-03 23:01 GMT+8 <a href=https://www.fool.com/investing/2021/12/03/5-warren-buffett-stocks-screaming-buys-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Making money for shareholders has been in Warren Buffett's blood since taking over as CEO of Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) in 1965. Over that time, he's led Berkshire to an average ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/03/5-warren-buffett-stocks-screaming-buys-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4106":"数据处理与外包服务","BK4504":"桥水持仓","BK4554":"元宇宙及AR概念","BK4553":"喜马拉雅资本持仓","BK4122":"互联网与直销零售","BK4503":"景林资产持仓","BK4566":"资本集团","TEVA":"梯瓦制药","BK4557":"大麻股","BK4524":"宅经济概念","BK4538":"云计算","BK4535":"淡马锡持仓","BK4559":"巴菲特持仓","BK4527":"明星科技股","BK4550":"红杉资本持仓","BK4007":"制药","V":"Visa","BK4533":"AQR资本管理(全球第二大对冲基金)","BRK.A":"伯克希尔","BK4534":"瑞士信贷持仓","BAC":"美国银行","BK4207":"综合性银行","BK4551":"寇图资本持仓","BK4507":"流媒体概念","BRK.B":"伯克希尔B","BK4561":"索罗斯持仓","AMZN":"亚马逊","BK4548":"巴美列捷福持仓","BK4532":"文艺复兴科技持仓","BMY":"施贵宝","BK4176":"多领域控股"},"source_url":"https://www.fool.com/investing/2021/12/03/5-warren-buffett-stocks-screaming-buys-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2188528084","content_text":"Making money for shareholders has been in Warren Buffett's blood since taking over as CEO of Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) in 1965. Over that time, he's led Berkshire to an average annual gain of about 20%, which translates into aggregate gains, including the year-to-date performance of the Class A shares (BRK.A), of approximately 3,500,000%. Gains like this are why the investing world pays close attention to what the Oracle of Omaha is buying and selling.\nBased on the latest 13F filing with the Securities and Exchange Commission, Berkshire Hathaway has stakes in 45 securities. Among these 45 holdings, five Warren Buffett stocks stand out as screaming buys in December.\nBerkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.\nAmazon\nWhile I'm well aware this isn't going to win any points for originality, e-commerce kingpin Amazon (NASDAQ:AMZN) remains a surefire stock to own in Buffett's portfolio.\nMost people are familiar with Amazon for its dominant online marketplace. According to an August report from eMarketer, Amazon is expected to handle 41.4% of all U.S. online sales in 2021. That's about 34 percentage points higher than the next-closest competitor. The key, though, is that the company has signed up 200 million people to a Prime membership worldwide. The annual fees collected from these members helps to buoy razor-thin retail margins and allows Amazon to consistently undercut brick-and-mortar retailers on price.\nHowever, the company's future rests with its considerably higher-margin segments, such as cloud infrastructure services. Amazon Web Services (AWS) accounted for only 13.4% of net sales in the third quarter, yet contributed 61.8% of the company's operating income. Even with online sales slowing as coronavirus vaccination rates tick higher and life returns to some semblance of normal, Amazon's critical highest-margin segments (AWS, subscriptions, and advertising) continue to grow rapidly.\nIf Amazon were to simply hit the median price-to-operating cash flow it's been trading at for the past 11 years, we could be looking at a $10,000 a share company by mid-decade.\nImage source: Getty Images.\nBristol Myers Squibb\nAnother Warren Buffett stock that's quickly become a screaming buy is pharmaceutical company Bristol Myers Squibb (NYSE:BMY).\nBristol Myers' success is dependent on organically developing and growing its brand-name pharmaceutical portfolio, as well as leaning on acquisitions to push the needle higher.\nFrom an internal development perspective, some of the company's biggest wins include cancer immunotherapy Opdivo and oral anticoagulant Eliquis -- the latter of which was developed with Pfizer. Eliquis should push for $10 billion in sales for Bristol Myers this year, while Opdivo hit $7 billion in revenue last year. Opdivo is particularly intriguing given that it's being examined in dozens of clinical trials and has already received approval for 10 indications in the U.S. Label expansion opportunities, pricing power, and improved cancer screening diagnostics all have the potential to make this a $10 billion a year therapy.\nBristol Myers also made waves with its November 2019 acquisition of cancer and immunology drugmaker Celgene. Buying Celgene added a handful of blockbuster drugs to Bristol's portfolio, including multiple myeloma treatment Revlimid, which will potentially top $13 billion in 2021 sales. Revlimid is protected from an onslaught of generic competition for four more years, which means Bristol Myers will be generating bountiful cash flow in the meantime.\nAt just 7 times consensus forward-year earnings per share, it's an absolute steal.\nImage source: Getty Images.\nVisa\nThe recent sell-off in payment processing behemoth Visa (NYSE:V) makes it a screaming buy, too.\nOver the past couple of months, Wall Street and investors have raised concerns about payment facilitators like Square or cryptocurrencies eating into Visa's dominance. However, these concerns seem unfounded given Visa's utter dominance of the processing space. As of 2018, it held a 53% share of U.S. credit card network purchase volume, which was more than 30 percentage points higher than the next-closest competitor. I should also mention the U.S. is the leading market for consumption in the world.\nVisa's outperformance is also a function of its lending avoidance. By sticking to the processing side of the equation, the company avoids having to set aside capital to cover credit delinquencies during recessions. Not having to cover credit/loan losses is a big reason why Visa rebounds faster than other financial stocks and maintains a profit margin north of 50%.\nAnd have I mentioned that Visa is one of the smartest ways to play rapidly rising inflation? Since the company's fees are tied to the price of goods and services, its revenue and profits will grow as the price for goods and services rises.\nImage source: Getty Images.\nTeva Pharmaceutical Industries\nThe cheapest stock in Warren Buffett's portfolio, brand-name and generic-drug company Teva Pharmaceutical Industries (NYSE:TEVA), is begging to be bought as well. Teva can currently be purchased for a little more than 3 times Wall Street's consensus earnings per share in 2021 and 2022.\nUnlike Amazon, Bristol Myers, and Visa, Teva hasn't been firing on all cylinders. Since 2016, the company settled a bribery scandal, buried itself in debt after overpaying for generic-drugmaker Actavis, and has faced a mountain of litigation concerning its role in the opioid epidemic. But while there's reason to not give Teva a valuation premium, an earnings multiple of 3 is overly pessimistic given the steps being taken to right the ship.\nIn late 2017, Kare Schultz took over as CEO. He's a turnaround specialist who's taken clear steps to improve the business. During his tenure, net debt has been reduced from over $34 billion to around $22 billion, and annual operating expenses have been cut by a double-digit percentage. Teva is leaner than it's been in years and is capable of maintaining annual operating cash flow of $2 billion (or higher).\nFurthermore, there's light at the end of the tunnel when it comes to opioid litigation. A trial in California recently went in favor of drugmakers, which could put some bargaining power back in Teva's court. If Schultz can negotiate a national settlement where free or reduced-cost medicine, not cash, is the lure, Teva could probably double very quickly.\nImage source: Getty Images.\nBank of America\nThe final Warren Buffett stock to buy hand over fist in December is banking juggernaut Bank of America (NYSE:BAC).\nBank stocks like BofA are on the cusp of hitting their growth sweet spot. With inflation picking up, the Federal Reserve will more than likely need to act in 2022 or 2023 to raise interest rates. Boosting the federal funds target rate will lift the net interest income-earning potential of banks with outstanding variable-rate loans.\nAmong money-center banks, none is more interest-sensitive than Bank of America. The company's third-quarter earnings presentation points out that a 100-basis-point parallel shift in the interest rate yield curve would generate an estimated $7.2 billion in added net interest income over 12 months. Although we're unlikely to see a 100-basis-point shift in 12 months, we are on the verge of seeing higher interest rates significantly bolster BofA's profit potential.\nThe other impressive aspect of Warren Buffett's second-largest holding is its digitization efforts. Though you probably don't think of Bank of America as a tech-savvy business, the number of digital active users has grown to nearly 41 million, with 43% of all sales in the third quarter coming from online or mobile banking. This push to digitize has allowed the company to consolidate some of its branches in order to reduce costs.\nBank of America should be a no-brainer buy as it enters the sweet spot of its growth cycle.","news_type":1},"isVote":1,"tweetType":1,"viewCount":760,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":804477137,"gmtCreate":1627977423729,"gmtModify":1633754712896,"author":{"id":"4091059338128690","authorId":"4091059338128690","name":"CharlieHtay","avatar":"https://static.tigerbbs.com/0ae33e398b0a3ea162ebb41390c87740","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4091059338128690","idStr":"4091059338128690"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/804477137","repostId":"2156113951","repostType":4,"isVote":1,"tweetType":1,"viewCount":103,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807676542,"gmtCreate":1628036928886,"gmtModify":1633754218349,"author":{"id":"4091059338128690","authorId":"4091059338128690","name":"CharlieHtay","avatar":"https://static.tigerbbs.com/0ae33e398b0a3ea162ebb41390c87740","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4091059338128690","idStr":"4091059338128690"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/807676542","repostId":"1101001900","repostType":4,"isVote":1,"tweetType":1,"viewCount":51,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807678532,"gmtCreate":1628036899126,"gmtModify":1633754219399,"author":{"id":"4091059338128690","authorId":"4091059338128690","name":"CharlieHtay","avatar":"https://static.tigerbbs.com/0ae33e398b0a3ea162ebb41390c87740","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4091059338128690","idStr":"4091059338128690"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/807678532","repostId":"2156786341","repostType":4,"repost":{"id":"2156786341","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1628035725,"share":"https://www.laohu8.com/m/news/2156786341?lang=&edition=full","pubTime":"2021-08-04 08:08","market":"us","language":"en","title":"Big strategic decisions await Samsung's Lee as momentum builds for his parole","url":"https://stock-news.laohu8.com/highlight/detail?id=2156786341","media":"Reuters","summary":"SEOUL, Aug 4 (Reuters) - With bated breath, management at Samsung Electronics is waiting to see if t","content":"<p>SEOUL, Aug 4 (Reuters) - With bated breath, management at Samsung Electronics is waiting to see if the conglomerate's leader, Jay Y. Lee, will be released on parole this month.</p>\n<p>Support for his parole, both political and amongst the public, has grown amid anxiety that key strategic decisions are not being made at the South Korean tech giant.</p>\n<p>If he is released, Samsung would be able to move forward with major investment and M&A projects - decisions company sources say should only be made by Lee who has been unable to address them while he sits in jail convicted of bribery and embezzlement.</p>\n<p>In particular, a decision on the location of a $17 billion U.S. plant to produce advanced logic chips awaits his return, four Samsung sources told Reuters on condition of anonymity.</p>\n<p>\"The word is that the U.S. investment will be finalised when Vice Chairman Jay Y. Lee is back,\" said <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the people.</p>\n<p>Kinam Kim, head of chips and components at Samsung and one of the firm's three co-CEOs, made a rare direct appeal to President Moon Jae-in in June, arguing Lee's return was crucial.</p>\n<p>\"Semiconductors need large investment decisions and the decisions can only be made quickly when the head of the conglomerate is present,\" Moon's office quoted Kim as saying.</p>\n<p>Lee served one year of an initial 5-year sentence from August 2017 which was later suspended. That court decision was overturned and the sentence revised to 30 months</p>\n<p>putting him back in jail in January this year. Having served some 18 months, he has just become eligible for release.</p>\n<p>The Justice Ministry last month eased parole eligibility guidelines for first-time offenders with good behaviour like Lee to 60% of sentence term served. The average eligible time for all criminals in South Korea was 80% prior to the easing.</p>\n<p>Lee's parole is expected to be reviewed on Aug. 9, and within Samsung hopes are high that he will be freed around Aug. 15 when the country celebrates Independence Day and pardons have traditionally been issued, three of the Samsung sources said.</p>\n<p>The Justice Ministry and Samsung declined to comment.</p>\n<p>If paroled, Lee would need the Justice Minister to approve his return to work as the law bars persons from working for companies involved in certain convictions for five years. He is likely to get that, legal experts say, as the amount deemed embezzled has been repaid.</p>\n<p>While there have been some protests against an early release for Lee and civic groups have voiced opposition, public support for his early release is at about 70%, according to two polls.</p>\n<p>A parliamentary committee leader has also voiced his support while other members of the ruling party have visited Samsung's chip complex noting that Lee is eligible for parole.</p>\n<p>Support on social media ranges from those who think he has already paid his dues while others fret that without Lee at the helm, South Korea's flagship conglomerate will fall behind competitors at a time when there is a global chip shortage and rivals like TSMC and Intel Corp are making large investments</p>\n<p><b>CASH PILE AWAITS USE</b></p>\n<p>South Korea's biggest conglomerates are still owned and controlled by their founding families and there is little precedence for handing over the reins to non-family members even when a senior family member has been jailed.</p>\n<p>On one hand, Samsung's day-to-day operations have been little affected by Lee's stints in prison. Operating profit in the latest quarter surged 54% and while he was jailed in 2017, Samsung reported its second-largest annual profit of 53.6 trillion won ($46.6 billion).</p>\n<p>But experts say Samsung's organisational structure makes it difficult for anyone besides Lee to sign off on strategic decisions that draw on cash pooled from its three main divisions - mobile, consumer electronics and chips.</p>\n<p>\"Realistically, risky strategic decisions like M&A, multibillion dollar deals, are left to the owner at Samsung,\" said Jaeyong Song, professor at Seoul National University and author of \"The Samsung Way\", a book about Samsung's management style.</p>\n<p>\"CEOs in Korea are more like chief operating officers in a way. They take care of the short-term profits, while the owner takes on long-term competitiveness because their tenure is for life.\"</p>\n<p>Analysts have also linked Lee's legal troubles to Samsung's huge pile of cash, which has swollen 57% over four years to stand at just under $100 billion as of end-June, noting it has not made a major acquisition since 2016.</p>\n<p>Chief Financial Officer Choi Yoon-ho told an earnings briefing in January the increase was mainly due to Samsung's inability to \"execute meaningful M&A activities\".</p>\n<p>In addition to the decision on the planned U.S. chip factory - which has come down to Austin, Texas which is widely seen as the favoured location, another area in Texas, New York or Arizona - Lee's return would likely trigger potential acquisitions of stakes in companies, analysts said.</p>\n<p>NXP Semiconductors NV, a Dutch maker of automotive chips with a market value of about $58 billion, has often been cited by analysts as a good fit for Samsung's strategic needs and a likely target. NXP declined to comment.</p>\n<p>Samsung SDI is considering an investment of at least $3.5 billion in the United States to produce batteries for electric vehicles, but a final decision will rest with a task force for the wider Samsung group and is unlikely to be made before the chip plant decision, one of the sources said.</p>\n<p>($1 = 1,151.4100 won)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Big strategic decisions await Samsung's Lee as momentum builds for his parole</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBig strategic decisions await Samsung's Lee as momentum builds for his parole\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-04 08:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SEOUL, Aug 4 (Reuters) - With bated breath, management at Samsung Electronics is waiting to see if the conglomerate's leader, Jay Y. Lee, will be released on parole this month.</p>\n<p>Support for his parole, both political and amongst the public, has grown amid anxiety that key strategic decisions are not being made at the South Korean tech giant.</p>\n<p>If he is released, Samsung would be able to move forward with major investment and M&A projects - decisions company sources say should only be made by Lee who has been unable to address them while he sits in jail convicted of bribery and embezzlement.</p>\n<p>In particular, a decision on the location of a $17 billion U.S. plant to produce advanced logic chips awaits his return, four Samsung sources told Reuters on condition of anonymity.</p>\n<p>\"The word is that the U.S. investment will be finalised when Vice Chairman Jay Y. Lee is back,\" said <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the people.</p>\n<p>Kinam Kim, head of chips and components at Samsung and one of the firm's three co-CEOs, made a rare direct appeal to President Moon Jae-in in June, arguing Lee's return was crucial.</p>\n<p>\"Semiconductors need large investment decisions and the decisions can only be made quickly when the head of the conglomerate is present,\" Moon's office quoted Kim as saying.</p>\n<p>Lee served one year of an initial 5-year sentence from August 2017 which was later suspended. That court decision was overturned and the sentence revised to 30 months</p>\n<p>putting him back in jail in January this year. Having served some 18 months, he has just become eligible for release.</p>\n<p>The Justice Ministry last month eased parole eligibility guidelines for first-time offenders with good behaviour like Lee to 60% of sentence term served. The average eligible time for all criminals in South Korea was 80% prior to the easing.</p>\n<p>Lee's parole is expected to be reviewed on Aug. 9, and within Samsung hopes are high that he will be freed around Aug. 15 when the country celebrates Independence Day and pardons have traditionally been issued, three of the Samsung sources said.</p>\n<p>The Justice Ministry and Samsung declined to comment.</p>\n<p>If paroled, Lee would need the Justice Minister to approve his return to work as the law bars persons from working for companies involved in certain convictions for five years. He is likely to get that, legal experts say, as the amount deemed embezzled has been repaid.</p>\n<p>While there have been some protests against an early release for Lee and civic groups have voiced opposition, public support for his early release is at about 70%, according to two polls.</p>\n<p>A parliamentary committee leader has also voiced his support while other members of the ruling party have visited Samsung's chip complex noting that Lee is eligible for parole.</p>\n<p>Support on social media ranges from those who think he has already paid his dues while others fret that without Lee at the helm, South Korea's flagship conglomerate will fall behind competitors at a time when there is a global chip shortage and rivals like TSMC and Intel Corp are making large investments</p>\n<p><b>CASH PILE AWAITS USE</b></p>\n<p>South Korea's biggest conglomerates are still owned and controlled by their founding families and there is little precedence for handing over the reins to non-family members even when a senior family member has been jailed.</p>\n<p>On one hand, Samsung's day-to-day operations have been little affected by Lee's stints in prison. Operating profit in the latest quarter surged 54% and while he was jailed in 2017, Samsung reported its second-largest annual profit of 53.6 trillion won ($46.6 billion).</p>\n<p>But experts say Samsung's organisational structure makes it difficult for anyone besides Lee to sign off on strategic decisions that draw on cash pooled from its three main divisions - mobile, consumer electronics and chips.</p>\n<p>\"Realistically, risky strategic decisions like M&A, multibillion dollar deals, are left to the owner at Samsung,\" said Jaeyong Song, professor at Seoul National University and author of \"The Samsung Way\", a book about Samsung's management style.</p>\n<p>\"CEOs in Korea are more like chief operating officers in a way. They take care of the short-term profits, while the owner takes on long-term competitiveness because their tenure is for life.\"</p>\n<p>Analysts have also linked Lee's legal troubles to Samsung's huge pile of cash, which has swollen 57% over four years to stand at just under $100 billion as of end-June, noting it has not made a major acquisition since 2016.</p>\n<p>Chief Financial Officer Choi Yoon-ho told an earnings briefing in January the increase was mainly due to Samsung's inability to \"execute meaningful M&A activities\".</p>\n<p>In addition to the decision on the planned U.S. chip factory - which has come down to Austin, Texas which is widely seen as the favoured location, another area in Texas, New York or Arizona - Lee's return would likely trigger potential acquisitions of stakes in companies, analysts said.</p>\n<p>NXP Semiconductors NV, a Dutch maker of automotive chips with a market value of about $58 billion, has often been cited by analysts as a good fit for Samsung's strategic needs and a likely target. NXP declined to comment.</p>\n<p>Samsung SDI is considering an investment of at least $3.5 billion in the United States to produce batteries for electric vehicles, but a final decision will rest with a task force for the wider Samsung group and is unlikely to be made before the chip plant decision, one of the sources said.</p>\n<p>($1 = 1,151.4100 won)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SMSN.UK":"三星","SMSD.UK":"三星电子","SSNLF":"三星电子"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156786341","content_text":"SEOUL, Aug 4 (Reuters) - With bated breath, management at Samsung Electronics is waiting to see if the conglomerate's leader, Jay Y. Lee, will be released on parole this month.\nSupport for his parole, both political and amongst the public, has grown amid anxiety that key strategic decisions are not being made at the South Korean tech giant.\nIf he is released, Samsung would be able to move forward with major investment and M&A projects - decisions company sources say should only be made by Lee who has been unable to address them while he sits in jail convicted of bribery and embezzlement.\nIn particular, a decision on the location of a $17 billion U.S. plant to produce advanced logic chips awaits his return, four Samsung sources told Reuters on condition of anonymity.\n\"The word is that the U.S. investment will be finalised when Vice Chairman Jay Y. Lee is back,\" said one of the people.\nKinam Kim, head of chips and components at Samsung and one of the firm's three co-CEOs, made a rare direct appeal to President Moon Jae-in in June, arguing Lee's return was crucial.\n\"Semiconductors need large investment decisions and the decisions can only be made quickly when the head of the conglomerate is present,\" Moon's office quoted Kim as saying.\nLee served one year of an initial 5-year sentence from August 2017 which was later suspended. That court decision was overturned and the sentence revised to 30 months\nputting him back in jail in January this year. Having served some 18 months, he has just become eligible for release.\nThe Justice Ministry last month eased parole eligibility guidelines for first-time offenders with good behaviour like Lee to 60% of sentence term served. The average eligible time for all criminals in South Korea was 80% prior to the easing.\nLee's parole is expected to be reviewed on Aug. 9, and within Samsung hopes are high that he will be freed around Aug. 15 when the country celebrates Independence Day and pardons have traditionally been issued, three of the Samsung sources said.\nThe Justice Ministry and Samsung declined to comment.\nIf paroled, Lee would need the Justice Minister to approve his return to work as the law bars persons from working for companies involved in certain convictions for five years. He is likely to get that, legal experts say, as the amount deemed embezzled has been repaid.\nWhile there have been some protests against an early release for Lee and civic groups have voiced opposition, public support for his early release is at about 70%, according to two polls.\nA parliamentary committee leader has also voiced his support while other members of the ruling party have visited Samsung's chip complex noting that Lee is eligible for parole.\nSupport on social media ranges from those who think he has already paid his dues while others fret that without Lee at the helm, South Korea's flagship conglomerate will fall behind competitors at a time when there is a global chip shortage and rivals like TSMC and Intel Corp are making large investments\nCASH PILE AWAITS USE\nSouth Korea's biggest conglomerates are still owned and controlled by their founding families and there is little precedence for handing over the reins to non-family members even when a senior family member has been jailed.\nOn one hand, Samsung's day-to-day operations have been little affected by Lee's stints in prison. Operating profit in the latest quarter surged 54% and while he was jailed in 2017, Samsung reported its second-largest annual profit of 53.6 trillion won ($46.6 billion).\nBut experts say Samsung's organisational structure makes it difficult for anyone besides Lee to sign off on strategic decisions that draw on cash pooled from its three main divisions - mobile, consumer electronics and chips.\n\"Realistically, risky strategic decisions like M&A, multibillion dollar deals, are left to the owner at Samsung,\" said Jaeyong Song, professor at Seoul National University and author of \"The Samsung Way\", a book about Samsung's management style.\n\"CEOs in Korea are more like chief operating officers in a way. They take care of the short-term profits, while the owner takes on long-term competitiveness because their tenure is for life.\"\nAnalysts have also linked Lee's legal troubles to Samsung's huge pile of cash, which has swollen 57% over four years to stand at just under $100 billion as of end-June, noting it has not made a major acquisition since 2016.\nChief Financial Officer Choi Yoon-ho told an earnings briefing in January the increase was mainly due to Samsung's inability to \"execute meaningful M&A activities\".\nIn addition to the decision on the planned U.S. chip factory - which has come down to Austin, Texas which is widely seen as the favoured location, another area in Texas, New York or Arizona - Lee's return would likely trigger potential acquisitions of stakes in companies, analysts said.\nNXP Semiconductors NV, a Dutch maker of automotive chips with a market value of about $58 billion, has often been cited by analysts as a good fit for Samsung's strategic needs and a likely target. NXP declined to comment.\nSamsung SDI is considering an investment of at least $3.5 billion in the United States to produce batteries for electric vehicles, but a final decision will rest with a task force for the wider Samsung group and is unlikely to be made before the chip plant decision, one of the sources said.\n($1 = 1,151.4100 won)","news_type":1},"isVote":1,"tweetType":1,"viewCount":87,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
